Kite and Daiichi Sankyo update cell therapy licensing agreement
Pharmaceutical Technology
DECEMBER 8, 2022
Kite Pharma and Daiichi Sankyo have updated a partnership agreement signed in 2017 for the former’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer.
Let's personalize your content